Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

BACKGROUND: Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. OBJECTIVE: To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (MTX), in patients with active rheumatoid arthritis (RA). METHODS: An international, multicentre, phase 3, randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, J, Landewé, R B, Mease, P, Brzezicki, J, Mason, D, Luijtens, K, van Vollenhoven, R F, Kavanaugh, A, Schiff, M, Burmester, G R, Strand, V, Vencovský, J, van der Heijde, D
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674556/
https://www.ncbi.nlm.nih.gov/pubmed/19015207
http://dx.doi.org/10.1136/ard.2008.101659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674556/
https://www.ncbi.nlm.nih.gov/pubmed/19015207
http://dx.doi.org/10.1136/ard.2008.101659

Ejemplares similares